NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.

The NCCN Task Force on Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry was convened to critically evaluate the extent to which the presence of the estrogen receptor (ER) and progesterone receptor (PgR) biomarkers in breast cancer serve as prognostic and predictive factors in the adjuvant and metastatic settings, and the ability of immunohistochemical (IHC) detection of ER and PgR to provide an accurate assessment of the expression of these biomarkers in breast cancer tumor tissue. The task force is a multidisciplinary panel of 13 experts in breast cancer who are affiliated with NCCN member institutions and represent the disciplines of pathology, medical oncology, radiation oncology, surgical oncology, and biostatistics. The main overall conclusions of the task force are ER is a strong predictor of response to endocrine therapy; ER status of all samples of invasive breast cancer or ductal carcinoma in situ (DCIS) should be evaluated by IHC; IHC measurements of PgR, although not as important clinically as ER, can provide useful information and should also be performed on all samples of invasive breast cancer or DCIS; IHC is the main testing strategy for evaluating ER and PgR in breast cancer and priority should be given to improve the quality of IHC testing methodologies; all laboratories performing IHC assays of ER and PgR should undertake formal validation studies to show both technical and clinical validation of the assay in use; and all laboratories performing IHC assays of hormone receptors in breast cancer should follow additional quality control and assurance measures as outlined in the upcoming guidelines from the American Society of Clinical Oncology and College of American Pathologists.

[1]  Graham A. Colditz,et al.  Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study , 2011, Breast Cancer Research and Treatment.

[2]  Seema A Khan,et al.  NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  R. Gelber,et al.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[5]  Heinrich Sticht,et al.  Estrogen and progesterone receptors: from molecular structures to clinical targets , 2009, Cellular and Molecular Life Sciences.

[6]  C. Perou,et al.  Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  W. Han,et al.  The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer. , 2009, American journal of surgery.

[8]  G. Colditz,et al.  Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. , 2009 .

[9]  S. Fox,et al.  Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. J. van de Vijver,et al.  Estrogen receptor phenotypes defined by gene expression profiling. , 2009, Cancer treatment and research.

[11]  S. Fuqua,et al.  Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor α and its phosphorylation at serine 305 , 2009, Breast Cancer Research and Treatment.

[12]  Laura Biganzoli,et al.  Prognostic and predictive factors. , 2009, Cancer treatment and research.

[13]  P. Fitzgibbons,et al.  National HER2 proficiency test results using standardized quantitative controls: characterization of laboratory failures. , 2009, Archives of pathology & laboratory medicine.

[14]  D. Allred.  The utility of conventional and molecular pathology in managing breast cancer , 2008, Breast Cancer Research.

[15]  Clive R Taylor,et al.  Consensus Recommendations on Estrogen Receptor Testing in Breast Cancer By Immunohistochemistry , 2008, Applied immunohistochemistry & molecular morphology : AIMM.

[16]  D. Allred.  Commentary: hormone receptor testing in breast cancer: a distress signal from Canada. , 2008, The oncologist.

[17]  Jingqin Luo,et al.  Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics , 2008, Journal of the National Cancer Institute.

[18]  N. Habib,et al.  The phosphorylated membrane estrogen receptor and cytoplasmic signaling and apoptosis proteins in human breast cancer , 2008, Cancer.

[19]  Gianluca Bontempi,et al.  Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.

[20]  G. Colditz,et al.  Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer , 2008, Breast Cancer Research.

[21]  M. Dieci,et al.  Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. , 2008, The oncologist.

[22]  P. Lønning,et al.  Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? , 2008, The oncologist.

[23]  K. Hede.  Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing. , 2008, Journal of the National Cancer Institute.

[24]  M. Reymond,et al.  Lost in Translation? A Systematic Database of Gene Expression in Breast Cancer , 2008, Pathobiology.

[25]  M. Clemons,et al.  Changes in breast tumour receptor status with time: A prospective study assessing the impact of obtaining confirmatory biopsy at metastatic recurrence on patient management , 2008 .

[26]  G. Hortobagyi,et al.  Prognostic impact of discordance/concordance of triple-receptor expression between primary tumor and metastasis in patients with metastatic breast cancer , 2008 .

[27]  Edith A Perez,et al.  Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Allred,et al.  Problems and solutions in the evaluation of hormone receptors in breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  A. Gown.  Current issues in ER and HER2 testing by IHC in breast cancer , 2008, Modern Pathology.

[30]  R. Gelber,et al.  Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Jack Cuzick,et al.  Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Charles M. Perou,et al.  Ductal Carcinoma In situ and the Emergence of Diversity during Breast Cancer Evolution , 2008, Clinical Cancer Research.

[33]  Early Breast Cancer Trialists' Collaborative Group.  Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials , 2008, The Lancet.

[34]  R. Peto,et al.  Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. , 2008, Lancet.

[35]  I. Ellis,et al.  Expression profiling technology: its contribution to our understanding of breast cancer , 2007, Histopathology.

[36]  L. Goldstein,et al.  Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases , 2008, Breast Cancer Research and Treatment.

[37]  E. Levin,et al.  Estrogen receptors outside the nucleus in breast cancer , 2008, Breast Cancer Research and Treatment.

[38]  B. O’Malley,et al.  Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  I. Nagtegaal,et al.  Re-evaluating Adjuvant Breast Cancer Trials: Assessing Hormone Receptor Status by Immunohistochemical Versus Extraction Assays , 2007 .

[42]  D. Allred,et al.  Development of Standard Estrogen and Progesterone Receptor Immunohistochemical Assays for Selection of Patients for Antihormonal Therapy , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[43]  P. Neven,et al.  Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  R. Sainson,et al.  A Conserved Mechanism for Steroid Receptor Translocation to the Plasma Membrane* , 2007, Journal of Biological Chemistry.

[45]  D. Rimm,et al.  Quantitative analysis of estrogen receptor heterogeneity in breast cancer , 2007, Laboratory Investigation.

[46]  R. Gelber,et al.  Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  David L Rimm,et al.  Bimodal population or pathologist artifact? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  E. Perez,et al.  Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  R. Walker.  Immunohistochemical markers as predictive tools for breast cancer , 2007, Journal of Clinical Pathology.

[50]  C. Perou,et al.  Identification of a basal-like subtype of breast ductal carcinoma in situ. , 2007, Human pathology.

[51]  I. Ellis,et al.  The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast , 2006, Journal of Clinical Pathology.

[52]  D. Rimm,et al.  Immunohistochemistry and quantitative analysis of protein expression. , 2009, Archives of pathology & laboratory medicine.

[53]  M. Cronin,et al.  Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue , 2007, Breast Cancer Research and Treatment.

[54]  M. Rossing,et al.  Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients , 2007, Breast Cancer Research.

[55]  Karen A Gelmon,et al.  Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  F. Stossi,et al.  Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. , 2006, Molecular endocrinology.

[57]  R M Levenson,et al.  Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment II , 2006, Histopathology.

[58]  D. Berry,et al.  Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. , 2006, JAMA.

[59]  E. Levin,et al.  Nature of functional estrogen receptors at the plasma membrane. , 2006, Molecular endocrinology.

[60]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  R. Pietras.  Biologic basis of sequential and combination therapies for hormone-responsive breast cancer. , 2006, The oncologist.

[62]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[63]  S. Schnitt.  Estrogen receptor testing of breast cancer in current clinical practice: what's the question? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  Zhiyuan Hu,et al.  Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  C. Perou,et al.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.

[66]  S. Bogen,et al.  A molecular model of antigen retrieval using a peptide array. , 2006, American journal of clinical pathology.

[67]  D. Rimm,et al.  Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. , 2005, Journal of the National Cancer Institute.

[68]  A. Giordano,et al.  Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. , 2005, Endocrine-related cancer.

[69]  C. Osborne,et al.  Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  J. Horiguchi,et al.  Co-expressed type of ER and HER2 protein as a predictive factor in determining resistance to antiestrogen therapy in patients with ER-positive and HER2-positive breast cancer. , 2005, Oncology reports.

[71]  C. Caldas,et al.  Molecular classification and molecular forecasting of breast cancer: ready for clinical application? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[73]  D. Allred,et al.  The Assessment of Hormone Receptors in Breast Cancer by Immunohistochemistry , 2005 .

[74]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[75]  N. Sneige,et al.  Estrogen Receptor Analysis for Breast Cancer: Current Issues and Keys to Increasing Testing Accuracy , 2005, Advances in anatomic pathology.

[76]  A. Howell,et al.  Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes , 1996, Breast Cancer Research and Treatment.

[77]  C. Gomez-Fernandez,et al.  Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. , 2005, American journal of clinical pathology.

[78]  C. Geyer,et al.  Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma , 2005, Cancer.

[79]  S. Schnitt,et al.  Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. , 2005, American journal of clinical pathology.

[80]  A. Ramaioli,et al.  Different clinical impact of estradiol receptor determination according to the analytical method: a study on 1940 breast cancer patients over a period of 16 consecutive years , 2005, Breast Cancer Research and Treatment.

[81]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[82]  D. Allred,et al.  Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study , 2004, Modern Pathology.

[83]  C. Osborne,et al.  HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer , 2004, Clinical Cancer Research.

[84]  J. Itoh,et al.  Immunohistochemical Evaluation of Hormone Receptors in Breast Cancer: Which Scoring System Is Suitable for Highly Sensitive Procedures? , 2004, Applied immunohistochemistry & molecular morphology : AIMM.

[85]  A. Gown,et al.  Unmasking the mysteries of antigen or epitope retrieval and formalin fixation. , 2004, American journal of clinical pathology.

[86]  P. Hall,et al.  Prognostic and predictive factors. , 2004, Methods in molecular medicine.

[87]  S. Hilsenbeck,et al.  Time-dependence of hazard ratios for prognostic factors in primary breast cancer , 2004, Breast Cancer Research and Treatment.

[88]  Anthony W. Norman,et al.  Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model , 2004, Nature Reviews Drug Discovery.

[89]  Mårten Fernö,et al.  Comparison of Immunohistochemical and Biochemical Assay of Steroid Receptors in Primary Breast Cancer Clinical Associations and Reasons for Discrepancies , 2003, Acta oncologica.

[90]  N. Goldstein,et al.  Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. , 2003, American journal of clinical pathology.

[91]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[92]  V. Jordan,et al.  The estrogen receptor: a model for molecular medicine. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[93]  C. Osborne,et al.  Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  L. Layfield,et al.  Interlaboratory Variation in Results from Immunohistochemical Assessment of Estrogen Receptor Status , 2003, The breast journal.

[95]  G. Figtree,et al.  Truncated Estrogen Receptor &agr; 46-kDa Isoform in Human Endothelial Cells: Relationship to Acute Activation of Nitric Oxide Synthase , 2003, Circulation.

[96]  P. Falb,et al.  A Novel Quality Control Slide for Quantitative Immunohistochemistry Testing , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[97]  P. Regitnig,et al.  Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories , 2002, Virchows Archiv.

[98]  D. DeMets,et al.  Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  C Blake Gilks,et al.  Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. , 2002, American journal of clinical pathology.

[100]  S. Bogen,et al.  Synthetic peptides identified from phage-displayed combinatorial libraries as immunodiagnostic assay surrogate quality-control targets. , 2002, Clinical chemistry.

[101]  A. Douglas-Jones,et al.  Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma. , 2001, Journal of clinical pathology.

[102]  Jian-ming Zheng,et al.  Variation of ER status between primary and metastatic breast cancer and relationship to p53 expression☆ ☆ This study was supported by the National Natural Science Foundation of China (No. 39870753) and Changhai Hospital ‘123’ Project. , 2001, Steroids.

[103]  V. Speirs,et al.  Expression of alternatively spliced estrogen receptor alpha mRNAs is increased in breast cancer tissues , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[104]  D. McDonnell,et al.  The Human Estrogen Receptor-α Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor Modulators* , 2001, The Journal of Biological Chemistry.

[105]  D B Evans,et al.  Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[107]  M. Dowsett,et al.  Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. , 2001, Endocrine-related cancer.

[108]  L. Bobrow,et al.  Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. , 2001, American journal of clinical pathology.

[109]  D. Barnes,et al.  Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening , 2000, Journal of clinical pathology.

[110]  B. Jasani,et al.  Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries , 2000, Journal of clinical pathology.

[111]  S. Martino,et al.  Estrogen receptor (ER) and progesterone receptor (PgR), by ligand‐binding assay compared with ER, PgR and pS2, by immuno‐histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study , 2000, International journal of cancer.

[112]  D. Barnes,et al.  Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems , 2000, Journal of clinical pathology.

[113]  K. Keyomarsi,et al.  Expression of an estrogen receptor alpha variant protein in cell lines and tumors. , 2000, Molecular and cellular endocrinology.

[114]  B. Katzenellenbogen,et al.  Caveolin-1 Potentiates Estrogen Receptor α (ERα) Signaling , 1999, The Journal of Biological Chemistry.

[115]  B. Katzenellenbogen,et al.  Caveolin-1 potentiates estrogen receptor alpha (ERalpha) signaling. caveolin-1 drives ligand-independent nuclear translocation and activation of ERalpha. , 1999, The Journal of biological chemistry.

[116]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  J. Riera,et al.  Use of cultured cells as a control for quantitative immunocytochemical analysis of estrogen receptor in breast cancer. The Quicgel method. , 1999, American journal of clinical pathology.

[118]  P B Sigler,et al.  Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[119]  D. Allred,et al.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[120]  J. Gustafsson,et al.  Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. , 1997, The Journal of clinical endocrinology and metabolism.

[121]  Eva Enmark,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Human Estrogen Receptor �-Gene Structure, Chromosomal Localization, and Expression Pattern* , 2022 .

[122]  J. Gustafsson,et al.  Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. , 1997, Endocrinology.

[123]  D. Barnes,et al.  Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. , 1996, British Journal of Cancer.

[124]  R. Bast,et al.  Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.

[125]  R. Gray,et al.  Annual hazard rates of recurrence for breast cancer after primary therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[126]  G. Greene,et al.  Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. , 1996, Gynecologic oncology.

[127]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[128]  B. Asselain,et al.  Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. , 1996, British Journal of Cancer.

[129]  J. Graham,et al.  Preferential Stimulation of Human Progesterone Receptor B Expression by Estrogen in T-47D Human Breast Cancer Cells (*) , 1995, The Journal of Biological Chemistry.

[130]  D. Grignon,et al.  College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Summary. Members of the Cancer Committee. , 1995, Archives of pathology & laboratory medicine.

[131]  M. Sliwkowski,et al.  HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. , 1995, Oncogene.

[132]  H. Burke,et al.  Criteria for prognostic factors and for an enhanced prognostic system , 1993, Cancer.

[133]  D. Wilbur,et al.  Estrogen and progesterone receptor detection in archival formalin-fixed, paraffin-embedded tissue from breast carcinoma: a comparison of immunohistochemistry with the dextran-coated charcoal assay. , 1992, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[134]  W. L. McGuire,et al.  Breast cancer prognostic factors: evaluation guidelines. , 1991, Journal of the National Cancer Institute.

[135]  P Chambon,et al.  Two distinct estrogen‐regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. , 1990, The EMBO journal.

[136]  C. Redmond,et al.  Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  K. Horwitz,et al.  Multiple human progesterone receptor messenger ribonucleic acids and their autoregulation by progestin agonists and antagonists in breast cancer cells. , 1988, Molecular endocrinology.

[138]  ADJUVANT TAMOXIFEN IN THE MANAGEMENT OF OPERABLE BREAST CANCER: THE SCOTTISH TRIAL Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh , 1987, The Lancet.

[139]  D. Mutch,et al.  Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. , 1986, Cancer research.

[140]  E B Cox,et al.  Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. , 1986, Cancer research.

[141]  C. Redmond,et al.  Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[142]  M. Press,et al.  Structure and dynamics of the estrogen receptor. , 1986, Journal of steroid biochemistry.

[143]  E B Cox,et al.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. , 1985, Archives of pathology & laboratory medicine.

[144]  Beahrs Oh,et al.  The American Joint Committee on Cancer. , 1984 .

[145]  S. Aamdal,et al.  Estrogen receptors and long‐term prognosis in breast cancer , 1984, Cancer.

[146]  O. Beahrs.  The American Joint Committee on Cancer. , 1984, Bulletin of the American College of Surgeons.

[147]  K. Horwitz,et al.  In situ photolinked nuclear progesterone receptors of human breast cancer cells: subunit molecular weights after transformation and translocation. , 1983, Endocrinology.

[148]  K. Seibert,et al.  Hormone receptors in breast cancer , 1982 .

[149]  A. Manni,et al.  Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy , 1980, Cancer.

[150]  W. McGuire,et al.  The value of estrogen and progesterone receptors in the treatment of breast cancer , 1980, Cancer.

[151]  M. Lippman,et al.  Lack of estrogen receptor associated with an increased response rate to cytotoxic chemotherapy in metastatic breast cancer? , 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[152]  R. Hähnel,et al.  Prognostic value of estrogen receptors in primary breast cancer , 1979, Cancer.

[153]  E. J. Gregory,et al.  Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. , 1977, Cancer research.

[154]  W. McGuire.  Estrogen receptors in human breast cancer. , 1973, The Journal of clinical investigation.

[155]  C. D. HAAGENSEN,et al.  Diseases of the Breast , 1972 .

[156]  E. Jensen.  On the Mechanism of Estrogen Action , 2015, Perspectives in biology and medicine.

[157]  E. Rynearson.  ENDOCRINE THERAPY , 1941 .